OTSUKA NOVEL PRODUCTS GMBH (OTSUKA)

https://otsuka-onpg.com/

PARTNER

Otsuka Novel Product GmbH (ONPG), Munich, Germany is Marketing Authorisation Holder of Deltyba® (delamanid) in Europe. ONPG is held at 100% share by Otsuka Pharmaceutical Co., Ltd. (OPC), Tokyo, Japan. OPC has expertise in TB drug screening, pre-clinical and clinical development. Delamanid has been successfully developed for the treatment of MDR-TB. A second novel anti-TB drug (OPC-167832) is currently in early stage clinical development.

Sign up to stay informed


    We will process your data to deliver our quarterly updates to your inbox. You can view our Privacy Policy here or contact us at info@eu-pearl.eu